INC280 inhibits Wnt/β-catenin and EMT signaling pathways and its induce apoptosis in diffuse gastric cancer positive for c-MET amplification

Sung-Hwa Sohn1†, Bohyun Kim1†, Hee Jung Sul1, Yoo Jin Kim1, Hyeong Su Kim2, Hongtae Kim5, Jong Bok Seo3, Youngho Koh4 and Dae Young Zang1,2*

Abstract
Objective: Gastric cancer is more open related to genetic predisposition. In our RNA sequencing study on gastric cancer patients, Runt-related transcription factor-3 (RUNX3) expression was significantly down-regulated in gastric cancer. We showed that decreased levels of RUNX3 are significantly associated with c-MET ($r = -0.4216$, $P = 0.0130$). In addition, c-MET expression is a candidate for targeted therapy in gastric cancer. Therefore, in the present study, the anti-cancer effects of the c-MET inhibitor on gastric cancer cells from positive or negative for c-MET amplification were evaluated.

Results: INC280 treatment inhibits growth of a c-MET-amplified MKN45 (RUNX3-positive) and SNU620 (RUNX3-negative) diffuse type cells. Then, INC280 showed the highest inhibition and apoptotic rates with the lowest IC50s in MKN45 cells but not in c-MET-reduced MKN28 (intestinal type) cells. We also showed that INC280 inhibits the WNT signaling pathway and SNAIL expression in MKN45 cells. The data indicate that INC280 could be used as therapeutic agents for the prevention or treatment of diffuse gastric cancer positive for c-MET amplification.

Keywords: INC280, Gastric cancer, c-MET, RUNX3, Diffuse type

Introduction
High-incidence areas of GC include Eastern Europe, South America, and East Asia [1–3]; however, the mortality rates have decreased markedly in recent years [4]. In Korea, despite a decline in the incidence of GC, it remains the second most common cancer [5]. In addition, unsatisfactory treatment outcomes are caused by differences in the histological classifications of GC between the intestinal- and diffuse-type. Intestinal-type GC is related to Helicobacter pylori infection and diffuse-type GC is more open related to genetic predisposition. Thus, diffuse-type is less related to environmental factors [6]. To overcome this problem, and to develop and identify new drug candidates, determining tumor characteristics and treatment parameters is important.

The Wnt/β-catenin signaling pathway and EMT are associated with a wide range of GC progression events. EMT was observed in the invasive progression of cancer that initiates diffuse GC in the absence of hyper-proliferation and β-catenin activation [7]. SNAIL, a key transcriptional repressor of E-cadherin expression, is a well-known trigger of EMT, leading to irreversible tumorigenesis in mice [8]. Recent studies have revealed that downregulation of the proto-oncogene MET suppresses EMT in prostate cancer [9]. Moreover, MET amplification is a frequent molecular abnormality in GC [10, 11].
In the present study, we applied an RNA-seq approach to identify MET and RUNX3 genes differentially expressed in the GC and adjacent normal tissues from 34 patients. We evaluated the effects of INC280 on the suppression of GC proliferation, migration, and apoptosis according to Lauren’s classification.

**Main text**

**Methods**

**Materials**

INC280 was supplied from Novartis (Basel, Switzerland). The compounds were dissolved in dimethyl sulfoxide at 10 mmol/L prior to use in all in vitro studies.

**Human gastric tissue specimen collection**

The GC and adjacent normal tissues obtained from 34 patients were approved by the Ethics Committee of Hallym University Sacred Heart Hospital (2015-I078) and were selected as the discovery cohort for RNA-seq. Additional file 1: Table S1 summarizes the discovery sets.

**RNA-seq analysis**

RNA-seq experimental procedures were performed using standard procedures. The raw reads were saved in the FASTQ format, and the dirty raw reads were removed before analyzing the data. Reads that could be uniquely mapped to a gene were used to calculate the gene expression levels, which were measured based on the number of reads per kilobase of transcript per million mapped reads. We identified differentially expressed genes between paired tumor and normal samples, and a \( P \) value \( \leq 0.001 \) was deemed to indicate statistical significance.

**Cell lines and cell culture**

The human GC cell lines SNU5, SNU16, SNU620, MKN7, MKN28, MKN45, MKN74, AGS, and KATO-III were obtained from the KCLB (Seoul, Korea). Cell culture was performed using standard procedures.

**Growth inhibition assays**

The IC\(_{50}\) values of INC280 on SNU620, MKN28 and MKN45 cells were measured using the MTS assay for the selected drugs at concentrations of 10, 1, 0.1, 0.05, 0.0025, 0.00125, 0.001, 0.0001, 0.00001 or 0.000001 \( \mu \)M for 48 h. On the day of the proliferation assay, the medium was removed, and 200 \( \mu \)L of fresh medium was added to each well of the 96-well plates, followed by 20 \( \mu \)L of MTS solution, and the plates were incubated at 37 °C for 2 h in a humidified environment with 5% CO\(_2\). The absorbance was read at 490 nm using a Synergy-2 Multi-Mode Microplate Reader (BioTek). The IC\(_{50}\) values were determined after fitting growth inhibition curves to dose–response curves using GraphPad Prism software (GraphPad Software Inc., USA).

**Cell migration assay**

MKN28 and MKN45 cells were diluted and seeded at a density of about 1 \( \times 10^5 \) cells per well in 6-cm plates. After incubation for 1 day, a straight scratch was made on the cells using a P200 pipette tip. The cells were then washed with phosphate-buffered saline and were further cultured with or without INC280 in RPMI1640. After incubation for 0, 24, and 72 h, the gap width of the scratch re-population was photographed and then compared with the initial gap size at 0 h.

**Apoptosis analysis**

The MKN28, SNU620, and MKN45 cells seeded into 6-well plates at a density 5 \( \times 10^4 \) cells per millilitre were treated with IC\(_{50}\) values of INC280. Cell death was determined using the annexin V-APC/PI apoptosis detection kit (Thermo Fisher Scientific, USA) using a CytoFLEX flow cytometer (Beckman Coulter, USA). The percentage of intact and apoptotic cells were calculated using CytExpert software (Beckman Coulter).

**qRT-PCR analysis**

To quantitate mRNA expression, the total RNA from each sample was reverse-transcribed into cDNA using the High Capacity cDNA reverse Transcription Kit (Applied Biosystems, USA). qRT-PCR was performed using the Power SYBR Green PCR Master mix and a LightCycler 96 instrument (Roche Applied Science, USA). The transcript levels of GAPDH were used for sample normalization. Primer sequences are listed in Additional file 1: Table S2.

**Immunoblot analysis**

Immunoblot analysis was performed using standard procedures. The antibodies are listed in detail in Additional file 1: Table S3.

**Immunofluorescence microscopy**

MKN45 cell cultured on chamber slides were washed with PBS and fixed with 4% paraformaldehyde, after which they were incubated with anti-β-catenin monoclonal antibody (BD Transduction Laboratories) and stained with anti-mouse IgG Alexa Fluor 488 (Invitrogen). Cells were examined using a ZEISS LSM700 confocal laser scanning microscope (Carl Zeiss, Oberkochen, Germany).

**Statistical analysis**

The data were statistically analyzed using Prism 5. All values are presented as mean± standard error of the
mean. Statistical significance was examined using the Mann–Whitney test and Fisher’s exact test. The Kaplan–Meier method was used to estimate OS, and differences between genotypes were compared by using the log-rank method. A P value < 0.05 was deemed to indicate statistical significance.

Results
Baseline characteristics
Thirty-four subjects were enrolled in the genetic alterations study using RNA-seq, and we identified differentially expressed genes such as MET and RUNX3. The associations of MET and RUNX3 expression with clinicopathological characteristics are shown in Additional file 1: Table S1. We found a correlation between the down-regulation of RUNX3 and MET overexpression (Fig. 1a), whereas only one (SNU620) cells showed a correlation pattern (Fig. 1b). Low expression of RUNX3 was significantly associated with poor differentiation (52.9%; P < 0.001), high expression of Ki-67 (79.4%; P < 0.001), diffuse-type histology (41.2%; P < 0.001) and recurrence (100%; P < 0.001) (Additional file 1: Table S1). OS analysis comparing contribution of MET or RUNX3 genotype of GC showed no statistically significant differences (log-rank P = 0.1346 and P = 0.4200, respectively; Fig. 1c). In this study, MET amplification doesn’t associated with a poor outcome. It is probably because MET amplification is present in 2–20% of GC patients, however, only 7% of tumors overexpressed p-MET in overexpressed MET [12], p-MET was significantly associated with poor outcome [13].

Determining the effective dose of INC280 in intestinal and diffuse-type cells
To investigate the effect of the INC280 on c-MET amplified cell with or without RUNX3, c-MET and RUNX3 protein expression was evaluated in GC cells. c-MET and RUNX3 proteins were expressed in SNU5 and MKN45 cells. Interestingly, p-MET amplified gastric cancer cell lines belong to the diffuse-type (Fig. 1b). We tested the
dose-dependent inhibitory effects of INC280 in MKN28 (intestinal-type), SNU620 (RUNX3-negative diffuse-type), and MKN45 (RUNX3-positive diffuse-type) cells (Fig. 2). The cells were treated with different concentrations of INC280 for 48 h, and the optimal dose was determined by evaluating the cell viability using MTS assays. Treatment with the INC280 decreased the cell viability in a dose-dependent manner in c-MET-amplified SNU620 and MKN45 cells but not in c-MET-reduced MKN28 cells (n = 3) (Fig. 2). The IC_{50} value of INC280 was determined using non-linear regression analysis [IC_{50} = 1.7 nM (MKN45) or 2.4 nM (SNU620)].

**Effects of INC280 on cell migration**

To determine the inhibitory effects of INC280 on MKN28 and MKN45 cells, cell migration was examined by wound-healing assay using the respective IC_{50} values of INC280 (Additional file 2: Figure S1). The wound gaps in the c-MET-amplified MKN45 cells treated with INC280 were significantly wider than those of treated c-MET-reduced MKN28 cells. INC280 showed an inhibitory effect on the c-MET-amplified cell line.

**Effects of INC280 on cell apoptosis**

To evaluate the effects of INC280 on cell death in MKN28, SNU620, and MKN45 cells, apoptosis was examined by staining with annexin V-APC/PI, followed by flow cytometry (Additional file 2: Figure S2). Cells were stained with annexin V-APC and PI, which assess early apoptotic and late apoptotic cell populations, respectively. INC280 showed the best cell death rates in SNU620 and MKN45 cells but not in MKN28 cells. The percentage of apoptotic cells was 22.59% and 23.56 ± 1.08% after exposure to INC280 for 48 h, respectively. By contrast, these drugs were inactive against MKN28 cells, which express low levels of c-MET.

**INC280 inhibits c-MET activation and WNT/β-catenin signaling in RUNX3-positive diffuse-type cells**

To examine the inhibitory effects of INC280 on MKN28 and MKN45 cells, oncogenic pathways were examined by analyzing gene and protein expression (Fig. 3a–c). When cells were treated with INC280, the levels of GSK3β and E-cadherin were increased in MKN45 cells; by contrast, the levels of total c-MET, phosphorylated c-MET, β-catenin, Wnt/β-catenin downstream target gene (c-MYC, CCND1), angiogenic marker (CD31), and EMT marker (SNAIL) were decreased. However, these drugs were inactive against MKN28 cells. Confocal microscopy analysis of the cellular distribution of endogenous β-catenin on MKN45 cells showed a membranous staining pattern (Fig. 3d). Membranous β-catenin was highly reduced after 20 h of INC280 treatment. Surprisingly, treatment of MKN45 cells with INC280 that resulted in increased cell size. In mammalian cells, cell size increases when cell cycle progression is blocked [14]. INC280 may induce apoptosis and cell cycle arrest by degradation of cytosolic β-catenin.

**Discussion**

Cancer is a disease caused by genetic alterations. Therefore, we conducted RNA-seq in GC samples and their matched adjacent normal tissues to identify genetic alterations. The RNA-seq study showed that decreased levels of RUNX3 were significantly associated with c-MET, however cell lines were no correlated between RUNX3 and c-MET. RUNX3 loss is an early event in GC progression due to aberrant Wnt/β-catenin signaling [15–17], which mediates EMT in GC [18], a process whereby epithelial cells are converted into migratory and invasive cells [19, 20].

C-MET amplification is present in 2–20% of GC and is associated with a poor outcome [10, 11, 21, 22]. c-MET is known to activate cancer cell proliferation, migration and tumor invasiveness [23, 24]. Recent preclinical studies have revealed that c-MET inhibitors, including onartuzumab, foretinib, crizotinib, and PHA-665752, have failed in clinical trials in GC patients [25, 26]. Therefore, identifying an appropriate c-MET-positive GC group that is sensitive to c-MET inhibition is an urgent issue. Therefore, in the present study, c-MET inhibitor drugs were screened to determine whether they could be used as therapeutic agents for the treatment of GC using growth inhibition assays of MKN45 cells. Among the six c-MET inhibitor drugs tested, INC280 showed high inhibitory activity; therefore, this drug was selected for further study. INC280 works against putative c-MET-dependent...

![Fig. 2 Effect of INC280 in c-MET amplified gastric cancer cells positive or negative for RUNX3 expression. MKN28, SNU620, and MKN45 cells were treated with various concentrations of INC280 for 48 h. The values of cell viability were then normalized against that of the control](image-url)
Fig. 3  Effect of c-MET downregulation on RUNX3, SNAIL and the Wnt/β-catenin signaling pathway. mRNA expression of c-MET-RUNX3-regulated genes in MKN28 (a) and MKN45 (b) cells. c) Protein levels of c-MET-RUNX3-regulated genes in MKN28 and MKN45 cells. ***p < 0.001. d) A presentative confocal microscopy showing decreased of membrane bound β-catenin in INC280 treated MKN45 cells.
tumor types [27]. In the present study, INC280 showed increased inhibition and apoptotic rates, indicating therapeutic utility in MKN45 cells. When MKN45 cells were treated with INC280, the levels of total c-MET, phosphorylated c-MET, total β-catenin, CCND1, c-MYC, CD31, and SNAIL proteins or genes were decreased. By contrast, the levels of phosphorylated β-catenin, RUNX3, E-cadherin, and GSK-3β were increased. Our results additionally indicated that INC280 may suppress EMT through decreasing SNAIL expression. Indeed, our results showed that INC280, as well as GSK3β-mediated signaling, inhibits Wnt/β-catenin signaling by inhibiting c-MET phosphorylation in diffuse GC.

The results of this study indicate that c-MET and RUNX3 are differentially expressed in GCs compared with normal adjacent gastric mucosa and found a correlation between low RUNX3 levels and c-MET overexpression and tumor recurrence. INC280 shows significant inhibitory activity in c-MET-expressed diffuse GC. Our in vitro study strongly supports the clinical evaluation of INC280, which prevents c-MET-associated GC.

Limitations
Our study reports an association between MET and diffuse-type. However, the lack of significance in our study could be due to relatively small sample size. Although diffuse GC positive for c-MET amplification might serve as a predictor for poor outcome, it is considered as actionable target.

Additional files

Additional file 1: Table S1. Association of MET and RUNX3 expression with clinicopathological characteristics in 34 gastric cancer patients.

Table S2. List of oligonucleotides for real-time PCR. Table S3. List of antibodies and its characteristic.

Additional file 2: Figure S1. Wound-healing assay was used to assess the effect of INC280 on the migration ability of MKN28 and MKN45 cells. INC280-treated MKN45 cells showed suppressed migration ability compared with INC280-treated MKN28 cell lines. Figure S2. Effect of INC280 on cell death in MKN28, SNU620, and MKN45 cells. Flow cytometric analysis of INC280-induced apoptosis in A: MKN28 and MKN45, B: SNU620 cells. PI, propidium iodide.

Abbreviations
GC: gastric cancer; EMT: epithelial–mesenchymal transition; RUNX3: Runt-related transcription factor-3; RNA-seq: RNA sequencing; KCLB: Korean Cell Line Bank; PPTS: phosphate buffered saline; PI: propidium iodide; MTs: 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium; qRT-PCR: quantitative real-time polymerase chain reaction; GAPDH: glyceraldehydes-3-phosphate dehydrogenase.

Authors’ contributions
SH5 performed molecular experiments, analyzed data and drafted the article. YJK, BK and HJS performed molecular experiments. HSK analyzed the clinicopathological results, HK, JBS and YK study design, data interpretation and preparation of final version of the manuscript. DYZ study design, guided the analysis of data, critically reviewing the study and edited the manuscript. All authors read and approved the final manuscript.

Author details
1 Hallym Translational Research Institute, Hallym University Sacred Heart Hospital, Anyang 14066, Republic of Korea. 2 Division of Hematology-Oncology, Department of Internal Medicine, Hallym University Medical Center, Hallym University College of Medicine, 22, Gwanpyeong-ro 170beon-gil, Dongan-gu, Anyang-si, Gyeonggi-do 14086, Republic of Korea. 3 Korea Basic Research Institute Seoul Center, Seoul 02853, Republic of Korea. 4 Department of Bio-medical Gerontology, Ilisong Institute of Life Sciences, Hallym University, Anyang, Gyeonggi-do 14066, Republic of Korea. 5 School of Life Sciences, Ulsan National Institute of Science and Technology, Ulsan 689-798, Republic of Korea.

Acknowledgements
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Availability of data and materials
The datasets used and/or analyzed for the current study are available from the corresponding author on reasonable request.

Consent for publication
Not applicable.

Ethical approval and consent to participate
Ethical registry was obtained from the Institutional Review Board and Ethics Committee of Hallym University Sacred Heart Hospital prior to the beginning of the study under No. 2015–I078. Written, informed consent was obtained from all participants prior to their inclusion in this study.

Funding
This research was supported by the National R&D Program for Cancer Control, Ministry of Health and Welfare (1A17C0054), the National Research Foundation of Korea grant funded by the Korean Ministry of Science and ICT (NRF-2017R1A2B4005055), the Ministry of Food and Drug Safety (awarded in 2018, 18183MFD5491) of Korea, and Hallym University Research Fund but had no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 17 October 2018 Accepted: 6 March 2019

Published online: 11 March 2019

References
1. Peleteiro B, Severo M, La Vecchia C, Lunet N. Model-based patterns in stomach cancer mortality worldwide. Eur J Cancer Prev. 2014;23:524–31.
2. Peleteiro B, Barros S, Castro C, Ferro A, Morais S, Lunet N. Worldwide burden of gastric cancer in 2010 attributable to high sodium intake in 1990 and predicted attributable burden for 2030 based on exposures in 2010. Brit J Nutr. 2016;116:728–33.
3. Ferro A, Peleteiro B, Malvezzi M, Bosetti C, Bertuccio P, Levi F, Negri E, La Vecchia C, Lunet N. Worldwide trends in gastric cancer mortality (1980–2011), with predictions to 2015, and incidence by subtype. Eur J Cancer. 2014;50:1330–44.
4. Patru CL, Surlin V, Georgescu I, Patru E. Current issues in gastric cancer epidemiology. Rev Med Chir Soc Med Nat Iasi. 2013;117:199–204.
5. Jung KW, Won YJ, Kong HJ, Oh CM, Lee DH, Lee JS. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2011. Cancer Res Treat. 2014;46:109–23.
6. Retterspitz MF, Monig SP, Schechensberg S, Schneider PW, Holscher AH, Dienes HP, Baldus SE. Expression of (beta)-catenin, MUC1 and c-met in
diffuse-type gastric carcinomas: correlations with tumour progression and prognosis. Anticancer Res. 2010;30:4635–41.
7. Humar B, Blair V, Charlton A, More H, Martin I, Guilford P. E-cadherin deficiency incites gastric signet-ring cell carcinoma in mice and man. Cancer Res. 2009;69:2050–6.
8. Perez-Mancera PA, Perez-Caro M, Gonzalez-Herrero I, Flores T, Orfao A, de Herreros AG, Gutierrez-Adan A, Pintado B, Sagrera A, Sanchez-Martín M, et al. Cancer development induced by graded expression of Snail in mice. Hum Mol Genet. 2005;14:3449–61.
9. Wang S, Wang X, Li J, Meng S, Liang Z, Xu X, Zhu Y, Li S, Wu J, Xu M, et al. c-Met, CREB1 and EGFR are involved in miR-493-5p inhibition of EMT via AKT/GSK-3beta/Snail signaling in prostate cancer. Oncotarget. 2017;8:22303–13.
10. Kuniyasu H, Yasui W, Kitada Y, Yokozaki H, Ito H, Tahara E. Frequent amplification of the c-met gene in scirrhous type stomach cancer. Biochem Biophys Res Commun. 1992;189:227–32.
11. Nessling M, Solinai-Tolfo S, Wilgenbus KK, Borchart F, Lichter P. Mapping of chromosomal imbalances in gastric adenocarcinoma revealed amplified protooncogenes MYCN, MET, WNT2, and ERBB2. Genes Chromosom Cancer. 1998;23:307–16.
12. Janjigian YY, Tang LH, Coit DG, Kelsen DP, Francone TD, Weiser MR, Jhanwar SC, Shah MA. MET expression and amplification in patients with localized gastric cancer. Cancer Epidemiol Biomark Prev. 2011;20:1021–7.
13. Wu JG, Yu JW, Wu HB, Zheng LH, Ni XC, Li XQ, Du GY, Jiang BJ. Expressions of Runx3 is a key event in inducing precancerous state of the stomach. Hum Mol Genet. 2005;14:3449–61.
14. Fingar DC, Salama S, Tsou C, Harlow E, Blenis J. Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev. 2002;16:1472–87.
15. Li QL, Ito K, Sakakura C, Fukamachi H, Inoue K, Chi XZ, Lee KY, Nomura PM. Biosynthesis of the protein encoded by the c-met proto-oncogene. Oncogene. 1989;4:1383–8.
16. Parikh RA, Wang P, Beumer JH, Chu E, Appleman LJ. The potential roles of hepatocyte growth factor (HGF)-MET pathway inhibitors in cancer treatment. Oncotargets. Ther. 2014;7:969–83.
17. Smolen GA, Sordella R, Mihaylov B, Mohapatra G, Barmettler A, Archibald H, Kim WJ, Okimoto RA, Bell DW, Sgroi DC, et al. Amplification of MET identifies a small and aggressive subgroup of esophageal adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol. 2011;29:4803–10.
18. Song Y, Li ZX, Liu X, Wang R, Li LW, Zhang QY. The Wnt/beta-catenin and PI3K/Akt signaling pathways promote EMT in gastric cancer by epigenetic regulation via H3 lysine 27 acetylation. Tumor Biol. 2017;39:1–10.
19. Huang L, Wu RL, Xu AM. Epithelial–mesenchymal transition in gastric cancer. Am J Transl Res. 2015;7:2141–58.
20. Christiansen JJ, Rajasekaran AK. Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. Cancer Res. 2006;66:8319–26.
21. Lee J, Tran P, Klemperer SJ. Targeting the MET pathway in gastric and oesophageal cancers: refining the optimal approach. Clin Oncol (R Coll Radiol). 2016;28:e35–44.
22. Lennierz JK, Kwak EL, Ackerman A, Michael M, Fox SB, Berghethon K, Lauwers GY, Christensen JG, Wilner KD, Haber DA, et al. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol. 2011;29:4803–10.
23. Matsumoto K, Nakamura T. Hepatocyte growth factor (HGF) as a tissue organizer for organogenesis and regeneration. Biochem Biophys Res Commun. 1997;239:639–44.
24. Giordano S, Di Renzo MF, Narisimhan RP, Cooper CS, Rosa C, Comoglio PM. Expression of the protein encoded by the c-met proto-oncogene. Oncogene. 1989;4:1383–8.
25. Christiansen JJ, Rajasekaran AK. Reassessing epithelial to mesenchymal transition. Anticancer Res. 2006;26:8319–26.
26. Smolen GA, Sordella R, Mihaylov B, Mohapatra G, Barmettler A, Archibald H, Kim WJ, Okimoto RA, Bell DW, Sgroi DC, et al. Amplification of MET identifies a small and aggressive subgroup of esophageal adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol. 2011;29:4803–10.
27. Liu X, Wang Q, Yang G, Marando C, Koblish HK, Hall LM, Fridman JS, Behshad E, Wynn R, Li Y, et al. A novel kinase inhibitor, INCB28060, blocks hepatocyte growth factor (HGF)-MET pathway inhibitors in cancer treatment. Oncotargets Ther. 2014;7:969–83.
28. Huang L, Wu RL, Xu AM. Epithelial–mesenchymal transition in gastric cancer. Am J Transl Res. 2015;7:2141–58.
29. Christiansen JJ, Rajasekaran AK. Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. Cancer Res. 2006;66:8319–26.
30. Lee J, Tran P, Klemperer SJ. Targeting the MET pathway in gastric and oesophageal cancers: refining the optimal approach. Clin Oncol (R Coll Radiol). 2016;28:e35–44.
31. Lennierz JK, Kwak EL, Ackerman A, Michael M, Fox SB, Berghethon K, Lauwers GY, Christensen JG, Wilner KD, Haber DA, et al. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol. 2011;29:4803–10.
32. Matsumoto K, Nakamura T. Hepatocyte growth factor (HGF) as a tissue organizer for organogenesis and regeneration. Biochem Biophys Res Commun. 1997;239:639–44.
33. Giordano S, Di Renzo MF, Narisimhan RP, Cooper CS, Rosa C, Comoglio PM. Expression of the protein encoded by the c-met proto-oncogene. Oncogene. 1989;4:1383–8.
34. Christiansen JJ, Rajasekaran AK. Reassessing epithelial to mesenchymal transition. Anticancer Res. 2006;26:8319–26.
35. Smolen GA, Sordella R, Mihaylov B, Mohapatra G, Barmettler A, Archibald H, Kim WJ, Okimoto RA, Bell DW, Sgroi DC, et al. Amplification of MET identifies a small and aggressive subgroup of esophageal adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol. 2011;29:4803–10.
36. Christiansen JJ, Rajasekaran AK. Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. Cancer Res. 2006;66:8319–26.
37. Lee J, Tran P, Klemperer SJ. Targeting the MET pathway in gastric and oesophageal cancers: refining the optimal approach. Clin Oncol (R Coll Radiol). 2016;28:e35–44.
38. Lennierz JK, Kwak EL, Ackerman A, Michael M, Fox SB, Berghethon K, Lauwers GY, Christensen JG, Wilner KD, Haber DA, et al. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol. 2011;29:4803–10.
39. Matsumoto K, Nakamura T. Hepatocyte growth factor (HGF) as a tissue organizer for organogenesis and regeneration. Biochem Biophys Res Commun. 1997;239:639–44.
40. Giordano S, Di Renzo MF, Narisimhan RP, Cooper CS, Rosa C, Comoglio PM. Expression of the protein encoded by the c-met proto-oncogene. Oncogene. 1989;4:1383–8.
41. Christiansen JJ, Rajasekaran AK. Reassessing epithelial to mesenchymal transition. Anticancer Res. 2006;26:8319–26.
42. Smolen GA, Sordella R, Mihaylov B, Mohapatra G, Barmettler A, Archibald H, Kim WJ, Okimoto RA, Bell DW, Sgroi DC, et al. Amplification of MET identifi...